The management of coronary artery disease (CAD) has undergone a remarkable transformation over the past decades. Once characterized by a limited arsenal of medications, the therapeutic landscape for this leading cause of global morbidity and mortality has expanded dramatically. Today, clinicians have a sophisticated array of coronary artery disease drugs at their disposal, ranging from foundational statins to groundbreaking RNA-based agents that promise to redefine treatment paradigms. This evolution reflects a deeper understanding of the disease's pathophysiology and a shift towards more targeted, personalized approaches to care.

The Foundation of CAD Pharmacotherapy

The cornerstone of CAD management lies in a multi-pronged pharmacological approach designed to alleviate symptoms, halt disease progression, and prevent life-threatening events. Antiplatelet agents, such as aspirin and P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel), are fundamental in preventing thrombotic complications by inhibiting platelet aggregation. Simultaneously, beta-blockers, ACE inhibitors, and ARBs work to reduce myocardial oxygen demand, lower blood pressure, and improve cardiac function, particularly in patients who have experienced a myocardial infarction or have left ventricular dysfunction. These foundational therapies form the backbone of guideline-directed medical therapy, significantly reducing the risk of recurrent events.

The Statin Revolution and Beyond

The introduction of statins revolutionized CAD management by directly targeting the lipid component of atherosclerotic disease. These agents, by inhibiting HMG-CoA reductase, effectively lower LDL cholesterol and have been shown to reduce cardiovascular events even in individuals with normal baseline cholesterol levels, underscoring their pleiotropic benefits. While statins remain the first-line lipid-lowering therapy, a significant number of patients fail to achieve target LDL levels or experience intolerable side effects. This therapeutic gap has spurred the development of adjunctive therapies, including ezetimibe, which inhibits cholesterol absorption, and the emergence of PCSK9 inhibitors (alirocumab, evolocumab) that offer potent LDL reduction for high-risk or statin-intolerant patients.

Novel Mechanisms: Inflammation and Metabolic Modulation

Expanding the therapeutic focus beyond lipids, recent research has spotlighted the role of inflammation in CAD progression. Agents like low-dose colchicine and interleukin-1 beta inhibitors are being explored for their potential to reduce residual cardiovascular risk associated with inflammatory pathways. Furthermore, the cardioprotective benefits of medications initially developed for other indications have been a landmark discovery. Sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, originally designed for diabetes management, have demonstrated significant reductions in cardiovascular mortality and heart failure hospitalizations, independent of their glycemic effects, and are now being integrated into CAD treatment protocols.

The Frontier: RNA-Targeted and Gene-Based Therapies

The future of cardiovascular care is being shaped by the advent of RNA-targeted and gene-based therapies. Agents like inclisiran, a small interfering RNA (siRNA), offer durable LDL reduction with twice-yearly injections, dramatically improving patient adherence. Beyond cholesterol management, RNA-based approaches are being developed to target elevated lipoprotein(a) and other genetic drivers of atherosclerosis. Gene editing technologies like CRISPR-Cas9 are also being explored for their potential to permanently correct pathogenic variants underlying conditions such as familial hypercholesterolemia, heralding an era of precision medicine. The global market for IHD drugs is poised for substantial growth, fueled by an aging population, rising prevalence of metabolic risk factors, and continuous innovation. As healthcare systems worldwide invest in early diagnosis and advanced therapies, the market is projected to expand significantly, making effective coronary artery disease drugs more accessible and transforming the prognosis for millions living with this condition.